Carissa Amparo A. Bernardo,
Rafael S. Tomacruz Related Institution
Publication Sub Type
Philippine Journal of Obstetrics and Gynecology
A 38-year old G3P1 (1011) was diagnosed with Invasive Ductal Carcinoma of the right breast on her 23rd week of gestation. The malignancy was estrogen and progesterone receptor assay and HER2/neu negative. She subsequently had 5 cycles of Cyclophosphamide-Doxorubicin chemotherapy beginning at 25 weeks gestation, repeat cesarean section with bilateral salpingo-oophorectomy at 36 weeks gestation 4 more courses of chemotherapy with Docetaxel starting 1 month postpartum, modified radical mastectomy, and radiotherapy. With a strong family history of breast and ovarian cancers, she underwent genetic testing for the BRCA gene mutation. She was positive for deleterious mutations of BRCA1 and BRCA2. She subsequently underwent "risk-reducing" simple mastectomy of the contralateral breast 2 years postpartum. Three sisters between the ages of 40 and 50 were likewise discovered to have a variety of BRCA gene mutations, one of whom also developed breast cancer. All sisters subsequently had risk-reducing mastectomies and salpingo-oophorectomies.
The American Society of Clinical Oncology (ASCO) recommends genetic testing for cancer predisposition when the individual has a personal or family history suggestive of a cancer susceptibility syndrome. The benefits of genetic testing include a more precise estimation of cancer risks for the individual and her family members, and the identification of those individuals who could participate in risk-reducing surgeries in an effort to virtually eliminate the probability of developing a particular inherited malignancy. Risk-reducing bilateral simple mastectomy can be performed for high-risk women who have been
documented to carry the BRCA gene mutation. On the other hand, risk-reducing contralateral simple mastectomy isrecommended for women with breast cancer who previously underwent modified radical mastectomy (MRM). Consequently, risk-reducing bilateral salpingooophorectomy is strongly recommended in women with BRCA gene mutations because of the high mortality rate associated with ovarian cancer and the lack of effective screening and preventive approaches for this malignancy. References
1. Facts on Breast Cancer, Fact Sheet Philippine National Statistical Coordination Board, Regional Unit XII, No. 1: 2002.
3. Brose, M , Smyrk, T , Weber, B , Lynch, H T. "Genetic predisposition to cancer"
Cancer Etiology Section 3 , 168 - 180, 2007
6. Greer, B E, Goff, B A, Koh, W , Petersdorf, S H, Douglas, J G. "Cancer in the pregnant patient. Principles and Practice of Gynecologic Oncology"
2 nd Ed, Philadelphia: Lippincott-Raven 199, 598- 602,
7. Hahn, K M, Johnson, P H, Gordon, N , Kuerer, H , Middleton, L , Ramirez, M , Yang, W , Perkins, G , Hortobagyi, G N, Theriault, R L. "Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero"
107(6): 1219 - 122, September 2006. Retrieved from:
8. Berry, D L, Theriault, R L, Holmes, F A, Parisi, V M, Booser, D J, Singletary, S E, Buzdar, A U, Hortobagyi, G N. "Management of breast cancer during pregnancy using a standardized protocol"
J Clin Oncol
17(3): 855 - 861, March 1999. Retrieved from:
9. Ring, A E, Smith, I E, Jones, A , Shannon, C , Galani, E , Ellis, P A. "Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals"
J Clin Oncol
23(18): 4192 - 419, June 2005. Retrieved from:
11. Callahan, M J, Crum, C P, Medeiros, F , Kindelberger, D W, Elvin, J A, Garber, J E, Feltmate, C M, Berkowitz, R S, Muto, M G. "Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction"
J Clin Oncol
25(25): 3985 - 399, September 2007. Retrieved from:
13. Ichikawa, Y , Lemon, S J, Wang, S , Franklin, B , Watson, P , Knezetic, J A, Bewtra, C , Lynch, H T. "Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members"
Cancer Genet Cytogenet
112(1): 2 - 8, July 1999. Retrieved from:
14. Lynch, H , Casey, M J, Shaw, T , Lynch, J . "Hereditary factors in gynaecologic cancer"
CA Cancer J Clin 54, 309 - 326, 2004
15. Batista, L I, Lu, K H, Beahm, E K, Arun, B K, Bodurka, D C, Meric-Bernstam, F . "Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome"
14(8): 101, April 2008. Retrieved from:
17. Weitzel, J N, Lagos, V I, Cullinane, C A, Gambol, P J, Culver, J O, Blazer, K R, Palomares, M R, Lowstuter, K J, MacDonald, D J. "Limited family structure and BRCA gene mutation status in single cases of breast cancer"
297(23): 2587 - 259, June 2007. Retrieved from:
18. Colditz, G A, Rosner, B A, Chen, W Y, Holmes, M D, Hankinson, S E. "Risk factors for breast cancer according to estrogen and progesterone receptor status"
J Natl Cancer Inst
96(3): 218 - 228, February 2004. Retrieved from:
19. Shelly, W , Draper, M W, Krishnan, V , Wong, M , Jaffe, R B. "Selective estrogen receptor modulators: an update on recent clinical findings"
Obstet Gynecol Surv
63(3): 163 - 181, March 2008. Retrieved from:
20. Huang, H J, Neven, P , Drijkoningen, M , Paridaens, R , Wildiers, H , Van Limbergen, E , Berteloot, P , Amant, F , Vergote, I , Christiaens, M R. "Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer"
16(11): 1755 - 176, November 2005. Retrieved from:
21. Pruthi, S , Brandt, K R, Degnim, A C, Goetz, M P, Perez, E A, Reynolds, C A, Schomberg, P J, Dy, G K, Ingle, J N. "A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis"
Mayo Clin Proc
82(8): 999 - 1012, August 2007. Retrieved from:
23. Finch, A , Shaw, P , Rosen, B , Murphy, J , Narod, S A, Colgan, T J. "Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers"
100(1): 58 - 64, January 2006. Retrieved from:
24. Chen, L M, Yang, K Y, Little, s E, Cheung, M K, Caughey, A B. "Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families"
110(1): 18 - 25, July 2007. Retrieved from:
26. Ackermann, S , Lux, M P, Fasching, P A, Strissl, P , Renner, S P, Poehls, U , Bender, H G, Beckmann, M W. "Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers"
Eur J Cancer Prev
15(6): 474 - 479, December 2006. Retrieved from:
27. De Leon Matsuda, M L, Liede, A , Kwan, E , Mapua, C A, Cutiongco, E M, Tan, A , Borg, A , Narod, S A. "BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines"
Int J Cancer
98(4): 596 - 603, April 2002. Retrieved from:
28. Rebbeck, T , Kauff, N , Domcheck, S . "Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA 1 or BRCA 2 mutation carriers"
Journal of the National Cancer Institute , 2009